NASDAQ:ALDX Aldeyra Therapeutics (ALDX) Stock Forecast, Price & News $5.53 -0.33 (-5.63%) (As of 03:04 PM ET) Add Compare Share Share Today's Range$5.53▼$5.8450-Day Range$5.86▼$8.1252-Week Range$4.95▼$11.97Volume490,736 shsAverage Volume835,217 shsMarket Capitalization$324.06 millionP/E RatioN/ADividend YieldN/APrice Target$19.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Aldeyra Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside239.9% Upside$19.00 Price TargetShort InterestBearish11.46% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.35Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.08) to ($1.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.68 out of 5 starsMedical Sector861st out of 966 stocksPharmaceutical Preparations Industry401st out of 445 stocks 3.5 Analyst's Opinion Consensus RatingAldeyra Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.00, Aldeyra Therapeutics has a forecasted upside of 239.9% from its current price of $5.59.Amount of Analyst CoverageAldeyra Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted11.46% of the float of Aldeyra Therapeutics has been sold short.Short Interest Ratio / Days to CoverAldeyra Therapeutics has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.Change versus previous monthShort interest in Aldeyra Therapeutics has recently increased by 5.91%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAldeyra Therapeutics does not currently pay a dividend.Dividend GrowthAldeyra Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALDX. Previous Next 3.0 News and Social Media Coverage News SentimentAldeyra Therapeutics has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Aldeyra Therapeutics this week, compared to 2 articles on an average week.Search Interest13 people have searched for ALDX on MarketBeat in the last 30 days. This is an increase of 63% compared to the previous 30 days.MarketBeat Follows3 people have added Aldeyra Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aldeyra Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.30% of the stock of Aldeyra Therapeutics is held by insiders.Percentage Held by Institutions66.62% of the stock of Aldeyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Aldeyra Therapeutics are expected to decrease in the coming year, from ($1.08) to ($1.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aldeyra Therapeutics is -6.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aldeyra Therapeutics is -6.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAldeyra Therapeutics has a P/B Ratio of 2.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aldeyra Therapeutics (NASDAQ:ALDX) StockAldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.Read More ALDX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALDX Stock News HeadlinesSeptember 29, 2023 | markets.businessinsider.comFINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses to Contact the FirmSeptember 28, 2023 | stockhouse.comDEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the FirmOctober 4, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!September 28, 2023 | tmcnet.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aldeyra Therapeutics, Inc. (ALDX)September 26, 2023 | businesswire.comDeadline Alert: ALDX Investor Alert: Contact Bronstein, Gewirtz & Grossman, LLC to Actively Participate in the Aldeyra Therapeutics, Inc. Class Action LawsuitSeptember 26, 2023 | americanbankingnews.comAldeyra Therapeutics (NASDAQ:ALDX) Share Price Crosses Below 50 Day Moving Average of $7.42September 25, 2023 | stockhouse.comFRIDAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the FirmSeptember 24, 2023 | prnewswire.comALDX FINAL DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action - ALDXOctober 4, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!September 18, 2023 | msn.comEyeing Returns: Aldeyra's Shift From Lab To MarketSeptember 15, 2023 | finance.yahoo.comAldeyra Therapeutics, Inc. (NASDAQ:ALDX) has caught the attention of institutional investors who hold a sizeable 43% stakeSeptember 11, 2023 | stockhouse.comINVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the FirmSeptember 6, 2023 | stockhouse.comDEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the FirmAugust 31, 2023 | businesswire.comROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class ...August 24, 2023 | benzinga.comSHAREHOLDER ALERT: Levi & Korsinsky Notifies Aldeyra Therapeutics, Inc. (ALDX) Investors of a Class Action Lawsuit and Upcoming DeadlineAugust 24, 2023 | benzinga.comSHAREHOLDER ALERT: Levi & Korsinsky Notifies Aldeyra Therapeutics, Inc.(ALDX) Investors of a Class Action Lawsuit and Upcoming DeadlineAugust 21, 2023 | benzinga.comALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud LawsuitAugust 18, 2023 | stockhouse.comSHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the FirmAugust 17, 2023 | stockhouse.comSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the FirmAugust 14, 2023 | stockhouse.comINVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the FirmAugust 12, 2023 | benzinga.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders of a Class Action Against Aldeyra Therapeutics, Inc. and Certain Officers – ALDXAugust 11, 2023 | prnewswire.comROSEN, A TOP RANKED LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALDXAugust 11, 2023 | benzinga.comALDX Stock News: Shareholders with Significant Losses in Aldeyra Therapeutics, Inc. Should Contact Robbins LLPAugust 11, 2023 | benzinga.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aldeyra Therapeutics, Inc. (ALDX)August 11, 2023 | businesswire.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aldeyra Therapeutics, Inc. (ALDX)August 10, 2023 | msn.comOppenheimer Reiterates Aldeyra Therapeutics (ALDX) Outperform RecommendationAugust 9, 2023 | markets.businessinsider.comExpert Ratings for Aldeyra TherapeuticsSee More Headlines Receive ALDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aldeyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ALDX Company Calendar Last Earnings8/03/2023Today10/04/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALDX CUSIPN/A CIK1341235 Webwww.ampliphibio.com Phone781-761-4904Fax781-270-0630Employees15Year FoundedN/APrice Target and Rating Average Stock Price Forecast$19.00 High Stock Price Forecast$28.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+233.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,030,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-35.88% Return on Assets-29.97% Debt Debt-to-Equity Ratio0.08 Current Ratio9.96 Quick Ratio9.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.58 per share Price / Book2.21Miscellaneous Outstanding Shares58,600,000Free Float54,318,000Market Cap$334.02 million OptionableOptionable Beta1.10 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesTodd C. Brady (Age 48)M.D., Ph.D., Chief Executive Officer and Director Joshua Reed (Age 47)Chief Financial Officer David McMullin (Age 45)Chief Commercial Officer James A. Gow (Age 53)M.D., Senior Vice President of Clinical Development Stephen G. Machatha (Age 43)Ph.D., Senior Vice President, Technical Operation Key CompetitorsAmarinNASDAQ:AMRNPrecigenNASDAQ:PGENNurix TherapeuticsNASDAQ:NRIXUroGen PharmaNASDAQ:URGNLyell ImmunopharmaNASDAQ:LYELView All CompetitorsInstitutional OwnershipBarclays PLCBought 110,039 shares on 9/21/2023Ownership: 0.216%Wolverine Trading LLCBought 9,200 shares on 8/23/2023Ownership: 0.000%Affinity Asset Advisors LLCBought 150,000 shares on 8/21/2023Ownership: 0.256%California State Teachers Retirement SystemBought 56,712 shares on 8/21/2023Ownership: 0.097%Nuveen Asset Management LLCBought 129,453 shares on 8/16/2023Ownership: 0.221%View All Institutional Transactions ALDX Stock - Frequently Asked Questions Should I buy or sell Aldeyra Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALDX shares. View ALDX analyst ratings or view top-rated stocks. What is Aldeyra Therapeutics' stock price forecast for 2023? 2 equities research analysts have issued 1 year target prices for Aldeyra Therapeutics' stock. Their ALDX share price forecasts range from $14.00 to $28.00. On average, they predict the company's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 233.3% from the stock's current price. View analysts price targets for ALDX or view top-rated stocks among Wall Street analysts. How have ALDX shares performed in 2023? Aldeyra Therapeutics' stock was trading at $6.96 at the start of the year. Since then, ALDX shares have decreased by 18.1% and is now trading at $5.70. View the best growth stocks for 2023 here. Are investors shorting Aldeyra Therapeutics? Aldeyra Therapeutics saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 6,450,000 shares, an increase of 5.9% from the August 31st total of 6,090,000 shares. Based on an average daily volume of 646,300 shares, the short-interest ratio is presently 10.0 days. Currently, 11.5% of the company's stock are sold short. View Aldeyra Therapeutics' Short Interest. When is Aldeyra Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our ALDX earnings forecast. How were Aldeyra Therapeutics' earnings last quarter? Aldeyra Therapeutics, Inc (NASDAQ:ALDX) released its quarterly earnings data on Thursday, August, 3rd. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.16. What ETF holds Aldeyra Therapeutics' stock ? Invesco Dorsey Wright Healthcare Momentum ETF holds 172,465 shares of ALDX stock, representing 0.81% of its portfolio. What other stocks do shareholders of Aldeyra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aldeyra Therapeutics investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), KushCo (KSHB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Zosano Pharma (ZSAN), Novan (NOVN), Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI). What is Aldeyra Therapeutics' stock symbol? Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol "ALDX." How do I buy shares of Aldeyra Therapeutics? Shares of ALDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aldeyra Therapeutics' stock price today? One share of ALDX stock can currently be purchased for approximately $5.70. How much money does Aldeyra Therapeutics make? Aldeyra Therapeutics (NASDAQ:ALDX) has a market capitalization of $334.02 million. The biotechnology company earns $-62,030,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. How can I contact Aldeyra Therapeutics? Aldeyra Therapeutics' mailing address is 131 HARTWELL AVENUE SUITE 320, LEXINGTON MA, 02421. The official website for the company is www.ampliphibio.com. The biotechnology company can be reached via phone at 781-761-4904, via email at ir@ampliphibio.com, or via fax at 781-270-0630. This page (NASDAQ:ALDX) was last updated on 10/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aldeyra Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.